+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Anti-Tumor Injection Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

  • PDF Icon

    Report

  • 110 Pages
  • March 2025
  • Region: Global
  • Prof Research
  • ID: 5950742
Description Jump to:
Anti-tumor injections, including docetaxel, paclitaxel, bevacizumab, and rituximab, deliver potent cancer therapies intravenously, targeting cancers like breast, lung, and prostate. This segment thrives on precision, rapid efficacy, and hospital-based administration, driven by rising cancer rates and biologics innovation. The market faces high costs, biosimilar competition, and complex manufacturing requirements.

Market Size and Growth Forecast

The global anti-tumor injection market is valued at USD 50 billion to USD 60 billion in 2025, with a CAGR of 6.5% to 8.0% from 2025 to 2030, reaching USD 70 billion to USD 85 billion by 2030.

Regional Analysis

North America holds 35-40%, growing at 5.5-6.5%. The U.S. leads with advanced oncology care and biologics, trending toward biosimilars, while Canada follows with steady demand. Europe accounts for 25-30%, growing at 5.0-6.0%. Germany and the UK drive usage with hospital focus, emphasizing generics. Asia Pacific represents 25-30%, growing at 8.5-10.0%. China and India expand with local production, trending toward affordability. The Rest of the World holds 10-15%, growing at 6.0-7.0%, with Brazil prioritizing access.

Application Analysis

Breast cancer dominates with 20-25%, growing at 6.0-7.0%, driven by taxanes, with trends in combination therapies. Stomach cancer holds 10-15%, growing at 5.5-6.5%, focusing on docetaxel. Ovarian cancer accounts for 10-15%, growing at 6.5-7.5%, with paclitaxel trends. Lung cancer represents 15-20%, growing at 7.0-8.0%, driven by biologics. Testicular cancer holds 5-10%, growing at 5.5-6.5%, with niche use. Cervical cancer accounts for 5-10%, growing at 6.0-7.0%, with emerging therapies. Endometrial cancer holds 5-10%, growing at 6.0-7.0%, with targeted focus. Prostate cancer represents 5-10%, growing at 6.5-7.5%, with biologic trends. Bladder cancer accounts for 5-10%, growing at 6.0-7.0%, with hospital use. Others grow variably.

Product Type Analysis

Docetaxel injections hold 25-30%, growing at 6.0-7.0%, valued for broad efficacy, with trends in generics. Paclitaxel injections account for 25-30%, growing at 5.5-6.5%, focusing on combinations. Bevacizumab injections represent 15-20%, growing at 7.5-8.5%, with trends in biosimilars. Adalimumab injections hold 10-15%, growing at 6.5-7.5%, with niche oncology use. Rituximab injections account for 10-15%, growing at 7.0-8.0%, with immunotherapy trends. Others grow at 6.0-7.0%, with emerging biologics.

Key Market Players

  • Roche: A Swiss titan pioneering anti-tumor biologics like bevacizumab for global oncology.
  • Bayer: A German leader delivering innovative anti-tumor injections for diverse cancers.
  • Novartis: A Swiss innovator advancing injectable oncology therapies worldwide.
  • Pfizer: A U.S. giant crafting robust anti-tumor injections for hospital use.
  • Amgen: A U.S. biotech leader enhancing anti-tumor biologics with cutting-edge science.
  • Mabxience: A Spanish specialist producing high-quality biosimilars for oncology care.
  • Luoxin Pharmaceutical: A Chinese firm supplying affordable anti-tumor injections regionally.
  • Qilu Pharmaceutical: A Chinese titan delivering cost-effective oncology injectables.
  • Zhejiang Borui Biopharmaceutical: A Chinese innovator crafting anti-tumor solutions for Asia.
  • Fuxing Medicine: A Chinese expert expanding anti-tumor injection availability.
  • Yuekang Pharmaceutical: A Chinese leader producing oncology injectables for local markets.
  • Yuheng Pharmaceutical: A Chinese firm enhancing anti-tumor therapy access.
  • Hengrui Medicine: A Chinese powerhouse advancing injectable oncology formulations.
  • Huiyu Pharmaceutical: A Chinese specialist supplying anti-tumor injections regionally.
  • Changbaishan Pharmaceutical: A Chinese innovator delivering oncology therapies for hospitals.
  • Innovent Biologics: A Chinese biotech leader pioneering anti-tumor biologics.
  • Yifan Pharmaceutical: A Chinese firm crafting reliable anti-tumor injections.

Porter’s Five Forces Analysis

  • Threat of New Entrants: Medium. High R&D costs and regulatory barriers limit entry, but biosimilars and generics lower hurdles for established firms, particularly in high-growth regions like Asia Pacific.
  • Threat of Substitutes: Medium. Oral oncology drugs and non-injectable therapies compete, though injections’ rapid action and efficacy in acute settings maintain their critical role in hospital-based care.
  • Bargaining Power of Buyers: High. Hospitals and healthcare systems demand cost-effective, reliable injectables, leveraging bulk purchasing and reimbursement negotiations to secure favorable pricing and supply terms.
  • Bargaining Power of Suppliers: Medium. Specialized raw materials for biologics give suppliers some influence, though large players mitigate this through in-house production and diversified sourcing strategies.
  • Competitive Rivalry: High. A mix of global innovators and regional generic producers fuels intense competition, with differentiation driven by efficacy, safety profiles, pricing, and penetration into emerging markets.

Market Opportunities and Challenges

Opportunities

  • Cancer burden growth: Rising incidences of breast, lung, and ovarian cancers globally drive demand for anti-tumor injections, creating a robust market for both branded and generic options across diverse healthcare settings.
  • Biosimilar surge: Patent expirations for biologics like bevacizumab fuel biosimilar growth, particularly in Asia and Europe, enhancing affordability and access to advanced oncology care.
  • Combination therapy advancements: Pairing injections with immunotherapies or targeted drugs boosts efficacy, opening new therapeutic pathways and reinforcing their role in modern cancer treatment protocols.
  • Hospital demand stability: Increasing reliance on injectable therapies in acute care settings ensures steady demand, leveraging hospital infrastructure to deliver cutting-edge oncology solutions.

Challenges

  • Toxicity risks: Side effects like neutropenia and infusion reactions limit patient tolerability, pushing R&D toward safer formulations and challenging market leaders to maintain clinical trust.
  • High production costs: Complex manufacturing for biologics and injectables strains budgets, risking affordability issues in price-sensitive markets and pressuring margins amid generic competition.
  • Regulatory delays: Stringent approval processes for injectables across regions increase costs and delay market entry, complicating global supply chains and expansion strategies.
  • Oral therapy competition: The rise of convenient oral oncology drugs threatens injection share, requiring continuous innovation to justify their systemic delivery advantages in a shifting treatment landscape.

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1 Executive SummaryChapter 2 Abbreviation and Acronyms
Chapter 3 Preface
3.1 Research Scope
3.2 Research Sources
3.2.1 Data Sources
3.2.2 Assumptions
3.3 Research Method
Chapter 4 Market Landscape
4.1 Market Overview
4.2 Classification/Types
4.3 Application/End Users
Chapter 5 Market Trend Analysis
5.1 Introduction
5.2 Drivers
5.3 Restraints
5.4 Opportunities
5.5 Threats
Chapter 6 Industry Chain Analysis
6.1 Upstream/Suppliers Analysis
6.2 Anti-Tumor Injection Analysis
6.2.1 Technology Analysis
6.2.2 Cost Analysis
6.2.3 Market Channel Analysis
6.3 Downstream Buyers/End Users
Chapter 7 Latest Market Dynamics
7.1 Latest News
7.2 Merger and Acquisition
7.3 Planned/Future Project
7.4 Policy Dynamics
Chapter 8 Historical and Forecast Anti-Tumor Injection Market in North America (2020-2030)
8.1 Anti-Tumor Injection Market Size
8.2 Anti-Tumor Injection Market by End Use
8.3 Competition by Players/Suppliers
8.4 Anti-Tumor Injection Market Size by Type
8.5 Key Countries Analysis
8.5.1 United States
8.5.2 Canada
8.5.3 Mexico
Chapter 9 Historical and Forecast Anti-Tumor Injection Market in South America (2020-2030)
9.1 Anti-Tumor Injection Market Size
9.2 Anti-Tumor Injection Market by End Use
9.3 Competition by Players/Suppliers
9.4 Anti-Tumor Injection Market Size by Type
9.5 Key Countries Analysis
9.5.1 Brazil
9.5.2 Argentina
9.5.3 Chile
9.5.4 Peru
Chapter 10 Historical and Forecast Anti-Tumor Injection Market in Asia & Pacific (2020-2030)
10.1 Anti-Tumor Injection Market Size
10.2 Anti-Tumor Injection Market by End Use
10.3 Competition by Players/Suppliers
10.4 Anti-Tumor Injection Market Size by Type
10.5 Key Countries Analysis
10.5.1 China
10.5.2 India
10.5.3 Japan
10.5.4 South Korea
10.5.5 Southeast Asia
10.5.6 Australia
Chapter 11 Historical and Forecast Anti-Tumor Injection Market in Europe (2020-2030)
11.1 Anti-Tumor Injection Market Size
11.2 Anti-Tumor Injection Market by End Use
11.3 Competition by Players/Suppliers
11.4 Anti-Tumor Injection Market Size by Type
11.5 Key Countries Analysis
11.5.1 Germany
11.5.2 France
11.5.3 United Kingdom
11.5.4 Italy
11.5.5 Spain
11.5.6 Belgium
11.5.7 Netherlands
11.5.8 Austria
11.5.9 Poland
11.5.10 Russia
Chapter 12 Historical and Forecast Anti-Tumor Injection Market in MEA (2020-2030)
12.1 Anti-Tumor Injection Market Size
12.2 Anti-Tumor Injection Market by End Use
12.3 Competition by Players/Suppliers
12.4 Anti-Tumor Injection Market Size by Type
12.5 Key Countries Analysis
12.5.1 Egypt
12.5.2 Israel
12.5.3 South Africa
12.5.4 Gulf Cooperation Council Countries
12.5.5 Turkey
Chapter 13 Summary For Global Anti-Tumor Injection Market (2020-2025)
13.1 Anti-Tumor Injection Market Size
13.2 Anti-Tumor Injection Market by End Use
13.3 Competition by Players/Suppliers
13.4 Anti-Tumor Injection Market Size by Type
Chapter 14 Global Anti-Tumor Injection Market Forecast (2025-2030)
14.1 Anti-Tumor Injection Market Size Forecast
14.2 Anti-Tumor Injection Application Forecast
14.3 Competition by Players/Suppliers
14.4 Anti-Tumor Injection Type Forecast
Chapter 15 Analysis of Global Key Vendors
15.1 Roche
15.1.1 Company Profile
15.1.2 Main Business and Anti-tumor Injection Information
15.1.3 SWOT Analysis of Roche
15.1.4 Roche Anti-tumor Injection Revenue, Gross Margin and Market Share (2020-2025)
15.2 Bayer
15.2.1 Company Profile
15.2.2 Main Business and Anti-tumor Injection Information
15.2.3 SWOT Analysis of Bayer
15.2.4 Bayer Anti-tumor Injection Revenue, Gross Margin and Market Share (2020-2025)
15.3 Novartis
15.3.1 Company Profile
15.3.2 Main Business and Anti-tumor Injection Information
15.3.3 SWOT Analysis of Novartis
15.3.4 Novartis Anti-tumor Injection Revenue, Gross Margin and Market Share (2020-2025)
15.4 Pfizer
15.4.1 Company Profile
15.4.2 Main Business and Anti-tumor Injection Information
15.4.3 SWOT Analysis of Pfizer
15.4.4 Pfizer Anti-tumor Injection Revenue, Gross Margin and Market Share (2020-2025)
15.5 Amgen
15.5.1 Company Profile
15.5.2 Main Business and Anti-tumor Injection Information
15.5.3 SWOT Analysis of Amgen
15.5.4 Amgen Anti-tumor Injection Revenue, Gross Margin and Market Share (2020-2025)
15.6 Mabxience
15.6.1 Company Profile
15.6.2 Main Business and Anti-tumor Injection Information
15.6.3 SWOT Analysis of Mabxience
15.6.4 Mabxience Anti-tumor Injection Revenue, Gross Margin and Market Share (2020-2025)
15.7 Luoxin Pharmaceutical
15.7.1 Company Profile
15.7.2 Main Business and Anti-tumor Injection Information
15.7.3 SWOT Analysis of Luoxin Pharmaceutical
15.7.4 Luoxin Pharmaceutical Anti-tumor Injection Revenue, Gross Margin and Market Share (2020-2025)
15.8 Qilu Pharmaceutical
15.8.1 Company Profile
15.8.2 Main Business and Anti-tumor Injection Information
15.8.3 SWOT Analysis of Qilu Pharmaceutical
15.8.4 Qilu Pharmaceutical Anti-tumor Injection Revenue, Gross Margin and Market Share (2020-2025)
15.9 Zhejiang Borui Biopharmaceutical
15.9.1 Company Profile
15.9.2 Main Business and Anti-tumor Injection Information
15.9.3 SWOT Analysis of Zhejiang Borui Biopharmaceutical
15.9.4 Zhejiang Borui Biopharmaceutical Anti-tumor Injection Revenue, Gross Margin and Market Share (2020-2025)
15.10 Fuxing Medicine
15.10.1 Company Profile
15.10.2 Main Business and Anti-tumor Injection Information
15.10.3 SWOT Analysis of Fuxing Medicine
15.10.4 Fuxing Medicine Anti-tumor Injection Revenue, Gross Margin and Market Share (2020-2025)
15.11 Yuekang Pharmaceutical
15.11.1 Company Profile
15.11.2 Main Business and Anti-tumor Injection Information
15.11.3 SWOT Analysis of Yuekang Pharmaceutical
15.11.4 Yuekang Pharmaceutical Anti-tumor Injection Revenue, Gross Margin and Market Share (2020-2025)
15.12 Yuheng Pharmaceutical
15.12.1 Company Profile
15.12.2 Main Business and Anti-tumor Injection Information
15.12.3 SWOT Analysis of Yuheng Pharmaceutical
15.12.4 Yuheng Pharmaceutical Anti-tumor Injection Revenue, Gross Margin and Market Share (2020-2025)
15.13 Hengrui Medicine
15.13.1 Company Profile
15.13.2 Main Business and Anti-tumor Injection Information
15.13.3 SWOT Analysis of Hengrui Medicine
15.13.4 Hengrui Medicine Anti-tumor Injection Revenue, Gross Margin and Market Share (2020-2025)
15.14 Huiyu Pharmaceutical
15.14.1 Company Profile
15.14.2 Main Business and Anti-tumor Injection Information
15.14.3 SWOT Analysis of Huiyu Pharmaceutical
15.14.4 Huiyu Pharmaceutical Anti-tumor Injection Revenue, Gross Margin and Market Share (2020-2025)
15.15 Changbaishan Pharmaceutical
15.15.1 Company Profile
15.15.2 Main Business and Anti-tumor Injection Information
15.15.3 SWOT Analysis of Changbaishan Pharmaceutical
15.15.4 Changbaishan Pharmaceutical Anti-tumor Injection Revenue, Gross Margin and Market Share (2020-2025)
15.16 Innovent Biologics
15.16.1 Company Profile
15.16.2 Main Business and Anti-tumor Injection Information
15.16.3 SWOT Analysis of Innovent Biologics
15.16.4 Innovent Biologics Anti-tumor Injection Revenue, Gross Margin and Market Share (2020-2025)
15.17 Yifan Pharmaceutical
15.17.1 Company Profile
15.17.2 Main Business and Anti-tumor Injection Information
15.17.3 SWOT Analysis of Yifan Pharmaceutical
15.17.4 Yifan Pharmaceutical Anti-tumor Injection Revenue, Gross Margin and Market Share (2020-2025)
List of Tables and Figures
Table Abbreviation and Acronyms
Table Research Scope of Anti-Tumor Injection Report
Table Data Sources of Anti-Tumor Injection Report
Table Major Assumptions of Anti-Tumor Injection Report
Figure Market Size Estimated Method
Figure Major Forecasting Factors
Figure Anti-Tumor Injection Picture
Table Anti-Tumor Injection Classification
Table Anti-Tumor Injection Applications
Table Drivers of Anti-Tumor Injection Market
Table Restraints of Anti-Tumor Injection Market
Table Opportunities of Anti-Tumor Injection Market
Table Threats of Anti-Tumor Injection Market
Table COVID-19 Impact For Anti-Tumor Injection Market
Table Raw Materials Suppliers
Table Different Production Methods of Anti-Tumor Injection
Table Cost Structure Analysis of Anti-Tumor Injection
Table Key End Users
Table Latest News of Anti-Tumor Injection Market
Table Merger and Acquisition
Table Planned/Future Project of Anti-Tumor Injection Market
Table Policy of Anti-Tumor Injection Market
Table 2020-2030 North America Anti-Tumor Injection Market Size
Figure 2020-2030 North America Anti-Tumor Injection Market Size and CAGR
Table 2020-2030 North America Anti-Tumor Injection Market Size by Application
Table 2020-2025 North America Anti-Tumor Injection Key Players Revenue
Table 2020-2025 North America Anti-Tumor Injection Key Players Market Share
Table 2020-2030 North America Anti-Tumor Injection Market Size by Type
Table 2020-2030 United States Anti-Tumor Injection Market Size
Table 2020-2030 Canada Anti-Tumor Injection Market Size
Table 2020-2030 Mexico Anti-Tumor Injection Market Size
Table 2020-2030 South America Anti-Tumor Injection Market Size
Figure 2020-2030 South America Anti-Tumor Injection Market Size and CAGR
Table 2020-2030 South America Anti-Tumor Injection Market Size by Application
Table 2020-2025 South America Anti-Tumor Injection Key Players Revenue
Table 2020-2025 South America Anti-Tumor Injection Key Players Market Share
Table 2020-2030 South America Anti-Tumor Injection Market Size by Type
Table 2020-2030 Brazil Anti-Tumor Injection Market Size
Table 2020-2030 Argentina Anti-Tumor Injection Market Size
Table 2020-2030 Chile Anti-Tumor Injection Market Size
Table 2020-2030 Peru Anti-Tumor Injection Market Size
Table 2020-2030 Asia & Pacific Anti-Tumor Injection Market Size
Figure 2020-2030 Asia & Pacific Anti-Tumor Injection Market Size and CAGR
Table 2020-2030 Asia & Pacific Anti-Tumor Injection Market Size by Application
Table 2020-2025 Asia & Pacific Anti-Tumor Injection Key Players Revenue
Table 2020-2025 Asia & Pacific Anti-Tumor Injection Key Players Market Share
Table 2020-2030 Asia & Pacific Anti-Tumor Injection Market Size by Type
Table 2020-2030 China Anti-Tumor Injection Market Size
Table 2020-2030 India Anti-Tumor Injection Market Size
Table 2020-2030 Japan Anti-Tumor Injection Market Size
Table 2020-2030 South Korea Anti-Tumor Injection Market Size
Table 2020-2030 Southeast Asia Anti-Tumor Injection Market Size
Table 2020-2030 Australia Anti-Tumor Injection Market Size
Table 2020-2030 Europe Anti-Tumor Injection Market Size
Figure 2020-2030 Europe Anti-Tumor Injection Market Size and CAGR
Table 2020-2030 Europe Anti-Tumor Injection Market Size by Application
Table 2020-2025 Europe Anti-Tumor Injection Key Players Revenue
Table 2020-2025 Europe Anti-Tumor Injection Key Players Market Share
Table 2020-2030 Europe Anti-Tumor Injection Market Size by Type
Table 2020-2030 Germany Anti-Tumor Injection Market Size
Table 2020-2030 France Anti-Tumor Injection Market Size
Table 2020-2030 United Kingdom Anti-Tumor Injection Market Size
Table 2020-2030 Italy Anti-Tumor Injection Market Size
Table 2020-2030 Spain Anti-Tumor Injection Market Size
Table 2020-2030 Belgium Anti-Tumor Injection Market Size
Table 2020-2030 Netherlands Anti-Tumor Injection Market Size
Table 2020-2030 Austria Anti-Tumor Injection Market Size
Table 2020-2030 Poland Anti-Tumor Injection Market Size
Table 2020-2030 Russia Anti-Tumor Injection Market Size
Table 2020-2030 MEA Anti-Tumor Injection Market Size
Figure 2020-2030 MEA Anti-Tumor Injection Market Size and CAGR
Table 2020-2030 MEA Anti-Tumor Injection Market Size by Application
Table 2020-2025 MEA Anti-Tumor Injection Key Players Revenue
Table 2020-2025 MEA Anti-Tumor Injection Key Players Market Share
Table 2020-2030 MEA Anti-Tumor Injection Market Size by Type
Table 2020-2030 Egypt Anti-Tumor Injection Market Size
Table 2020-2030 Israel Anti-Tumor Injection Market Size
Table 2020-2030 South Africa Anti-Tumor Injection Market Size
Table 2020-2030 Gulf Cooperation Council Countries Anti-Tumor Injection Market Size
Table 2020-2030 Turkey Anti-Tumor Injection Market Size
Table 2020-2025 Global Anti-Tumor Injection Market Size by Region
Table 2020-2025 Global Anti-Tumor Injection Market Size Share by Region
Table 2020-2025 Global Anti-Tumor Injection Market Size by Application
Table 2020-2025 Global Anti-Tumor Injection Market Share by Application
Table 2020-2025 Global Anti-Tumor Injection Key Vendors Revenue
Figure 2020-2025 Global Anti-Tumor Injection Market Size and Growth Rate
Table 2020-2025 Global Anti-Tumor Injection Key Vendors Market Share
Table 2020-2025 Global Anti-Tumor Injection Market Size by Type
Table 2020-2025 Global Anti-Tumor Injection Market Share by Type
Table 2025-2030 Global Anti-Tumor Injection Market Size by Region
Table 2025-2030 Global Anti-Tumor Injection Market Size Share by Region
Table 2025-2030 Global Anti-Tumor Injection Market Size by Application
Table 2025-2030 Global Anti-Tumor Injection Market Share by Application
Table 2025-2030 Global Anti-Tumor Injection Key Vendors Revenue
Figure 2025-2030 Global Anti-Tumor Injection Market Size and Growth Rate
Table 2025-2030 Global Anti-Tumor Injection Key Vendors Market Share
Table 2025-2030 Global Anti-Tumor Injection Market Size by Type
Table 2025-2030 Anti-Tumor Injection Global Market Share by Type

Companies Mentioned

  • Roche
  • Bayer
  • Novartis
  • Pfizer
  • Amgen
  • Mabxience
  • Luoxin Pharmaceutical
  • Qilu Pharmaceutical
  • Zhejiang Borui Biopharmaceutical
  • Fuxing Medicine
  • Yuekang Pharmaceutical
  • Yuheng Pharmaceutical
  • Hengrui Medicine
  • Huiyu Pharmaceutical
  • Changbaishan Pharmaceutical
  • Innovent Biologics
  • Yifan Pharmaceutical

Related Topics

Related Reports

Facial Injectables Market by Type, End User - Global Forecast 2025-2030 - Product Image

Facial Injectables Market by Type, End User - Global Forecast 2025-2030

  • Report
  • 198 Pages
  • Global
From
Aesthetic Injectables Market by Product, Gender, Application, End User - Global Forecast 2025-2030 - Product Image

Aesthetic Injectables Market by Product, Gender, Application, End User - Global Forecast 2025-2030

  • Report
  • 181 Pages
  • Global
From
Bacteriostatic Water for Injection Market Report: Trends, Forecast and Competitive Analysis to 2030 - Product Image

Bacteriostatic Water for Injection Market Report: Trends, Forecast and Competitive Analysis to 2030

  • Report
  • 150 Pages
  • Global
From
Paclitaxel Injection Market Report 2025 - Product Image

Paclitaxel Injection Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Generic Oncology Sterile Injectable Market Report 2025 - Product Image

Generic Oncology Sterile Injectable Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.